AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Results of Operations and Financial Condition


AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On March 13, 2018, AVEO Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December31, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.

The information in this Item 2.02 of this Form8-Kand Exhibit 99.1 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02. Financial Statements and Exhibits.

EX-99.1 2 aveo-ex991_6.htm EX-99.1 aveo-ex991_6.htm     Exhibit 99.1   AVEO Reports Full Year 2017 Financial Results and Provides Business Update CAMBRIDGE,…
To view the full exhibit click here

About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

An ad to help with our costs